Silexion Therapeutics Warrant

SLXNW

Market cap $130K

SLXNW Hedge Fund Activity: Q1 2026 in Review

19 of the 8,151 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics Warrant (SLXNW) for Q1 2026, worth a combined $62K — down 25% from $83.1K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of SLXNW and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Goldman Sachs, adding an estimated $71. The largest seller was Blue Owl Capital Holdings, exiting entirely with an estimated $375 sold.

• 19 institutional investors held Silexion Therapeutics Warrant (SLXNW) as of Q1 2026, down from 22 in Q4 2025.
• Funds reported $62K of Silexion Therapeutics Warrant stock for Q1 2026, down 25% quarter-over-quarter.
• 0 funds opened new Silexion Therapeutics Warrant positions in Q1 2026 and 3 closed out, a net change of -3 holders.
• The largest Silexion Therapeutics Warrant buyer in Q1 2026 was Goldman Sachs, an estimated $71 added.
• The largest Silexion Therapeutics Warrant seller in Q1 2026 was Blue Owl Capital Holdings, an estimated $375 sold.

Based on aggregated 13F filings for Q1 2026.